subject: Gilead Sciences: Pharmavitae Profile - Market Research Report On Aarkstore Enterprise [print this page] Introduction Introduction
This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
Gain insight into Gileads strategic outlook across the next 6 years
Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Gilead over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the companys prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
Benchmark Gileads performance against key rivals in the prescription pharmaceutical sector
Assess the effects of the patent expiry of one of the components of Atripla on the company
See how the launch of two new products, Truvada + rilpivirine and the Quad pill, will generate new growth for the company
Table of Contents :
About Datamonitor Healthcare 2
About the PharmaVitae team 2
Chapter 1 About This Profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive Summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 200315 6
Financial performance, 200315 7
Gilead: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 14
Chapter 3 Quarterly News Update 22
Latest quarterly sales 22
Latest comment 22
Latest prescription pharma product news 25
Latest corporate news 28
Future product milestones 30
Chapter 4 Company Introduction 31
Key findings 31
Background 31
Key corporate developments 31
M&A history 32
Chapter 5 Company Sales 34
Key findings 34
Prescription pharmaceutical sales and growth rate analysis, 200315 35
Product analysis 37
Therapy area analysis 43
Geographic analysis 45
Launch/core/expiry analysis 47
Molecule type analysis 52
Externalization analysis 54
Chapter 6 Company Financials 57
Key findings 57
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 200309 58
